Mucin 1 peptide–major histocompatibility complex class I complex

The MUC1 peptide–MHC class I complex is a molecular assembly whereby a peptide fragment derived from Mucin 1, typically aberrantly expressed in cancer, is bound in the groove of an MHC class I molecule on the cell surface[10]. This presentation enables recognition by cytotoxic T cells, which can mediate immune clearance of abnormal cells. The specificity, affinity, and conformation of peptide binding to MHC-I are crucial for effective immune activation, with structural studies highlighting the importance of certain peptide residues for stable binding[1][8][10]. The MUC1 peptide–MHC complex serves as a target for novel immunotherapies, including peptide-based vaccines and adoptive cell therapies, and is important in the development of precision cancer immunotherapy strategies[5][10].

Other names

MUC1 peptide–MHC-I complexMUC1–peptide–MHCMUC1-derived peptide–MHC class I complex

Presentation of MUC1-derived peptides via MHC-I to cytotoxic T lymphocytes, activating targeted immune attack on cells expressing aberrant MUC1[7][10]